Bexion Pharmaceuticals
Chemicals & Related Products · Kentucky, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
632 Russell St, Covington, Kentucky, 410...Phone Number
(859) 446-7386Website
www.bexionpharma.comRevenue
<$5 MillionIndustry
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies to enhance the lives of cancer patients. Their lead product, BXQ-350, is a biologic that modulates sphingolipid metabolism to improve treatment outcomes for advanced solid tumors, particularly metastatic colorectal cancer. The company aims to address treatment resistance and improve tolerability of standard chemotherapy by leveraging a unique mechanism that promotes programmed cell death in cancer cells. Bexion's therapies are designed for patients facing challenging cancer diagnoses and aim to redefine treatment approaches in oncology.Explore more
Bexion Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Bexion Pharmaceuticals
Compare insights from companies similar to Bexion Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bexion Pharmaceuticals Tech Stack
A closer look at the technologies used by Bexion Pharmaceuticals
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Bexion Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies to enhance the lives of cancer patients. Their lead product, BXQ-350, is a biologic that modulates sphingolipid metabolism to improve treatment outcomes for advanced solid tumors, particularly metastatic colorectal cancer. The comp... Read More
